Pay in 4 interest-free payments of $6.41 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
Patients should expect their providers to ask more medical questions and document more carefully than they did during the shortage years
Retatrutide is a novel triple receptor agonist targeting GLP-1, GIP, and glucagon receptors under clinical evaluation for obesity and type 2 diabetes
GLP-1 medications were originally developed to manage type 2 diabetes, and research has revealed they may offer additional cardiovascular benefits including improvements in cholesterol and triglyceride levels
Participants also recorded reductions in waist circumference (average 7.1cm loss on 6mg, 8.2cm on 12mg, 10cm on 36mg, compared with 3.1cm loss on placebo), blood pressure (estimated -4.2 and -1mm HG difference between placebo and orforglipron in systolic and diatolic blood pressure, respectively) and cholesterol (-2.1% difference between placebo and orforglipron)
"What's interesting about it is people don't just lose weight and reach a plateau, they just keep losing weight," Dr
